Genomenon Recognized by Frost & Sullivan for Genomic Intelligence Solutions and Software for Pharma and Clinical Diagnostics Companies

Genomenon’s unique blend of AI technology and expert scientific review delivers deep genomic insights into genetic drivers of rare diseases and cancer.

SAN ANTONIO, May 8, 2023 /PRNewswire/ — Frost & Sullivan today announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the criteria and best practices identified as critical for the global pharma and clinical diagnostics genomics markets.

Genomenon is a genomic intelligence software company that combines AI-powered Genomic Language Processing (GLP) with expert review by genetic scientists to deliver the most comprehensive knowledgebase of genomic evidence available. Their fit-for-purpose combinatorial approach to identifying and indexing published genomic evidence gives them a unique advantage over other open access and commercial genomic data resources in this space.

Clinical diagnostic labs rely on Genomenon’s Mastermind Genomic Search Engine to find critical information needed to diagnose rare genetic diseases and identify the most appropriate patient treatment options. Pharmaceutical companies engaged in the development of rare disease therapeutics partner with Genomenon to gain deep insights into the genetic drivers of disease. The Genomenon scientific team leverages information in the Mastermind knowledgebase to provide the genomic intelligence pharmaceutical companies need to better understand disease mechanisms, more accurately estimate disease prevalence, design clinical trials, and prepare documentation for regulatory approvals.

Pavel Zhebrouski, a best practices research analyst at Frost & Sullivan, observed, “Genomenon differentiates itself in the space by providing a unique combination of AI technology and human expertise. Genomenon empowers rare disease pharmaceutical and biotechnology companies to make informed decisions about promising candidates in their pipeline and help propel novel therapeutics to market. Its commitment to innovation and creativity, scientific rigor, and accuracy, while achieving commercial success, differentiates it from competitors,” added Tejashri Khadilkar, Frost & Sullivan industry analyst.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Claudia Toscano
P: 1.956.533.5915
E: [email protected]

About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery and development. For more information, visit genomenon.com

Contact:
Candace Chapman
P: 1.734.794.3075 x708
E: [email protected]

SOURCE Frost & Sullivan

惠譽評級稱澳門2024年賭收將恢復至疫前水平79%

惠譽評級發表報告指出,儘管面臨中國大陸經濟疲軟的擔憂,澳門2024年賭收仍有望恢復至2019年水平的79%。

【特刊】遠東摩納哥 GT 賽車

時隔三年,FIA GT 世界盃重返澳門街頭,出賽陣容或許是迄今為止最令人印象深刻。賽事起源於頗受歡迎的職業業餘配對賽澳門 GT 盃,於2015年首辦並迅速成為全球 GT 車手夢寐以求的爭勝競技場。

【特刊】亞洲市場的門戶

東南亞的房車賽事一直呈現朝氣蓬勃的向上景象,其中以澳門格蘭披治大賽車尤為突出。澳門這項頂級運動賽事自2015年開始採用TCR賽事規則,今年更將創紀錄地一連舉辦三場TCR規格賽事。TCR概念策劃者Marcello Lotti解釋了TCR系列區內取得成功的原因。

布林肯承認援烏資金“肥水不流外人田” 俄大使說美從烏克蘭危機直接受益

新華社北京12月8日電 美國國務卿安東尼·布林肯7日說,美國對烏克蘭的軍事援助資金90%用於在美國本土生產援烏武器裝備,這讓美國經濟受益。

中國擴大免簽政策給相關國家民眾帶來實在便利

新華社北京12月8日電 中國自12月1日起對法國、德國、義大利、荷蘭、西班牙、馬來西亞6國實施單方面免簽入境政策,僅前三天6國就有近7000人次通過免簽來華,占到6國入境總人次的39%。多國人士表示,中國擴大免簽政策為暢通中外人員往來、促進旅遊業、經貿合作和人文交流帶來實實在在的便利。

深圳前海區為港澳醫療機構落戶提供最高2,000萬元獎勵

《深圳市前海深港現代服務業合作區支持港澳醫療機構集聚發展辦法》發布。 圍繞著港澳醫療機構的舉辦、營運、發展,創新提出了11項核心扶持措施。

30間公屋商舖租賃公開招標

澳門房屋局即日起為30間作飲食店或一般商業用途之公共房屋商舖租賃進行公開招標,以完善區內商業及生活配套。

聯合國否認美國關於加沙安全區的說法

新華社聯合國12月6日電(記者尚緒謙)針對美國官員稱加沙地帶居民可以去聯合國指定的安全點避難的說法,聯合國秘書長古特雷斯的發言人迪雅裏克5日說,加沙地帶“沒有聯合國指定的安全區”。

【特刊】荊棘滿途

澳門格蘭披治大賽車即將迎來70週年慶典,這是這項傳奇賽事歷史上的重要里程碑。然而,澳門大賽車的非凡旅程並非一帆風順,卻充滿了困難和障礙。

資訊氾濫時代 全球媒體人士齊呼堅守公信力

新華社廣州12月5日電(記者徐超 許嘉桐 馬曉澄)技術變革加速改變當前資訊傳播生態,讓每一個人都能成為資訊發佈者,也讓每一個人都承受著資訊超載、虛假誤導的壓力。傳統媒體在傳播資訊、引導輿論方面應如何發揮作用?全球媒體人士在第五屆世界媒體峰會期間展開深入探討,認為媒體面臨前所未有的挑戰,卻也肩負著前所未有的責任,應該回歸其價值本源,堅持真實客觀、專業理性,守住公信力這一最重要資產。

相關文章

【特刊】遠東摩納哥 GT 賽車

時隔三年,FIA GT 世界盃重返澳門街頭,出賽陣容或許是迄今為止最令人印象深刻。賽事起源於頗受歡迎的職業業餘配對賽澳門 GT 盃,於2015年首辦並迅速成為全球 GT 車手夢寐以求的爭勝競技場。

【特刊】亞洲市場的門戶

東南亞的房車賽事一直呈現朝氣蓬勃的向上景象,其中以澳門格蘭披治大賽車尤為突出。澳門這項頂級運動賽事自2015年開始採用TCR賽事規則,今年更將創紀錄地一連舉辦三場TCR規格賽事。TCR概念策劃者Marcello Lotti解釋了TCR系列區內取得成功的原因。

中國擴大免簽政策給相關國家民眾帶來實在便利

新華社北京12月8日電 中國自12月1日起對法國、德國、義大利、荷蘭、西班牙、馬來西亞6國實施單方面免簽入境政策,僅前三天6國就有近7000人次通過免簽來華,占到6國入境總人次的39%。多國人士表示,中國擴大免簽政策為暢通中外人員往來、促進旅遊業、經貿合作和人文交流帶來實實在在的便利。

深圳前海區為港澳醫療機構落戶提供最高2,000萬元獎勵

《深圳市前海深港現代服務業合作區支持港澳醫療機構集聚發展辦法》發布。 圍繞著港澳醫療機構的舉辦、營運、發展,創新提出了11項核心扶持措施。

【特刊】荊棘滿途

澳門格蘭披治大賽車即將迎來70週年慶典,這是這項傳奇賽事歷史上的重要里程碑。然而,澳門大賽車的非凡旅程並非一帆風順,卻充滿了困難和障礙。

【特刊】觀賞第 70 屆澳門格蘭披治大賽車的 7 個理由

《商訊》2023年11月特刊 | 第70屆澳門格蘭披治大賽車特刊